Sistema de Salut de Catalunya
[Rey-Reñones C] Research Support Unit-Camp de Tarragona, Catalan Institute of Health (ICS), Tarragona, Spain. IDIAP Jordi Gol, Catalan Institute of Health (ICS), Barcelona, Spain. School of Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, Spain. [Baena-Díez JM] IDIAP Jordi Gol, Catalan Institute of Health (ICS), Barcelona, Spain. La Marina Primary Care Center, Catalan Institute of Health (ICS), Barcelona, Spain. [Aguilar-Palacio I] Research Group in Health Services of Aragon, (GRISSA) IIS Aragón, University of Zaragoza, Zaragoza, Spain. [Miquel C] Department of Medicine, University of Barcelona, Barcelona, Spain. [Grau M] Serra Húnter Fellow, Department of Medicine, University of Barcelona, Barcelona, Spain. Biomedical Research Consortium in Epidemiology and Public Health (CIBERESP), Barcelona, Spain. IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain
Departament de Salut
2022-09-20T12:34:59Z
2022-09-20T12:34:59Z
2021-10-09
Type-2 diabetes mellitus; Epidemiology; Cancer
Diabetes tipo 2; Epidemiología; Cáncer
Diabetis tipus 2; Epidemiologia; Càncer
Individuals with type 2 diabetes mellitus are at greater risk of developing cancer and of dying from it. Both diseases are age-related, contributing to the impact of population aging on the long-term sustainability of health care systems in European Union countries. The purpose of this narrative review was to describe, from epidemiological, pathophysiological and preventive perspectives, the links between type 2 diabetes mellitus and the most prevalent cancers in these patients. Multiple metabolic abnormalities that may occur in type 2 diabetes mellitus, particularly obesity, could explain the increased cancer risk. In addition, the effectiveness of drugs commonly used to treat type 2 diabetes mellitus (e.g., metformin and thiazolidinediones) has been broadly evaluated in cancer prevention. Thus, a better understanding of the links between type 2 diabetes mellitus and cancer will help to identify the contributing factors and the pathophysiological pathways and to design personalized preventive strategies. The final goal is to facilitate healthy aging and the prevention of cancer and other diseases related with type 2 diabetes mellitus, which are among the main sources of disability and death in the European Union and worldwide.
Article
Published version
English
Diabetis no-insulinodependent; Oncologia - Malalties - Prevenció; DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2; DISEASES::Neoplasms; Other subheadings::Other subheadings::Other subheadings::/complications; ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II; ENFERMEDADES::neoplasias; Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones
MDPI
Biomedicines;9(10)
https://doi.org/10.3390/biomedicines9101429
Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/
